30
CARDIOVASCULAR
hamburger

Market-Leading Everolimus

The market-leading choice for XIENCE™ Stent is everolimus, which is a proven therapeutic drug.²

An ideal drug for DES has these characteristics:

  • Safe over the long term
  • Stable over time
  • Compatible with polymer
  • Cytostatic and anti-inflammatory
  • Effective at varying doses for a wide therapeutic window

The everolimus drug provides all these features.

Everolimus Elution Rate Matches Restenosis Cascade for Optimal Endothelization Rate3

The release of everolimus aligns with the vessel's restenosis cascade. This, in turn, maximizes the drug's efficacy against restenosis and minimizes the drug's effect of re-endothelialization, which facilitates vessel restoration and function.

Everolimus Elution Correlates to Restenosis Cascade

The Xience Stent drug elution profile shows that 100% of the drug is eluted at 120 days.

XIENCE™ Stent Uses Low Dose of Everolimus3,4

Everolimus is a well established anti-proliferative drug. The concentration of everolimus used with XIENCE™ Stent is low, at 100 µg/cm². These histological images below show healthy, fully healed vessels at a concentration that is 8x the dose used on the XIENCE™ stent. Images were gathered using a pre-clinical animal model.

Everolimus Safety at 8x Drug Dose

Everolimus safety at 8x its regular dose on XIENCE™ DES

References

  1. Zanchin C, et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675. Serruys P, et al. N Engl J Med. 2010;363:136-146. Shiomi H, et al. JACC Cardiovasc Interv. 2019;12:637-647. Kufner S, et al. Circulation. 2019:139(3):325-333. Palmerini T, et al. Lancet. 2013;379:1393-1402. Bangalore S, et al. Circulation. 2012;125:2873-2891. Bangalore S, et al. Circ Cardiovasc Interv. 2013;6(6):378-390. Pilgrim T, et al. Lancet. 2014;384:2111-2122. Pilgrim T, et al. Lancet. 2018;392:737-746. Data on file at Abbott.
  2. Instructions for Use, XIENCE Sierra™ Stent.
  3. Perkins L, et al. J Interven Cardiol. 2009;22:S28-S40; Bennett J, Biologics: Targets and Therapy. 2013;7:149-159; Meredith I et al. J Am Cardiol Intv. 2009;2:977-985.
  4. Tests performed and data on file at Abbott.

  • Manuals & Technical Resources
    Manuals & Technical Resources
  • Cardiovascular Products
    Cardiovascular Products
  • Customer Service
    Customer Service

MAT-2101779 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.